Filtros de búsqueda

Lista de obras de

Changes in patient profile, treatment effectiveness, and safety during 4 years of access to interferon-free therapy for hepatitis C virus infection

artículo científico publicado en 2020

Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis

artículo científico publicado en 2019

Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics

artículo científico publicado en 2021

Efficacy of HCV treatment in Poland at the turn of the interferon era - the EpiTer study

artículo científico publicado en 2016

Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study

artículo científico publicado en 2021

HCV Genotype Has No Influence on the Incidence of Diabetes—EpiTer Multicentre Study

artículo científico publicado en 2022

Hepatitis C Infection as a Risk Factor for Hypertension and Cardiovascular Diseases: An EpiTer Multicenter Study

artículo científico publicado en 2022

Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA

artículo científico publicado en 2020

Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection

artículo científico publicado en 2022

Prevalence of HCV genotypes in Poland - the EpiTer study

artículo científico publicado en 2016

The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study

scholarly article by Ewa Janczewska et al published 16 November 2018 in BMC Infectious Diseases

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda